Modern pharmacotherapy for chronic recurrent cystitis: problems and opportunities


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The paper provides an overview of current global approaches to pharmacotherapy for chronic recurrent cystitis, including non-antibacterial treatments. The urgency of this problem is associated with the extremely high prevalence of the disease in Russia and worldwide. The antimicrobial resistance in uropathogens has increased dramatically over the past two decades. In cases of recurrent cystitis, the routine management tactics for patients is to increase the time of, doses or to expand antibiotic therapy regimens, despite the lack of evidence supporting this treatment strategy. The lowest resistance of E. coli, the main pathogen of urinary tract infections, is noted for fosfomycin (0-2.9%), nitrofurans (0-4.4%) and mecillinam (0-4%).

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Shikh

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: chih@mail.ru
MD, professor, Department of clinical pharmacology and propaedeutics of internal diseases of the medical faculty

N. Lazareva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

MD, professor , Department of clinical pharmacology and propaedeutics of internal diseases of the medical faculty

E. Rebrova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: katrina1987@rambler.ru
h.D, associate Professor of the Department of clinical pharmacology and propaedeutics of internal diseases of the medical faculty

A. Ryazanova

olgograd State Medical University

Department of clinical pharmacology and intensive care with a course of clinical pharmacology of fuv, clinical Allergology

Әдебиет тізімі

  1. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am. 2014; 28: 1. https:// doi.org/1Q.1Q16/j.idc.2013.Q9.QQ3
  2. Tandogdu Z., Wagenlehner F.M. Global epidemiology of urinary tract infections. Curr. Opin. Infect. Dis. 2016; 29(1): 73-9. https://doi.org/10.1097/ QC0.0000000000000228.
  3. Ikaheimo R., Siitonen A., Heiskanen T., Karkkainen U., Kuosmanen P., Lipponen P., Makela PH. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin. Infect. Dis. 1996; 22: 91-9. https://doi.org/10.1093/clinids/22.1.91.
  4. Geerlings S.E. Clinical presentations and epidemiology of urinary tract infections. Microbiol. Spectr. 2016; 4(5). https://doi.org/10.1128/microbiolspec. UTI-0002-2012.
  5. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю., ред. Россйскиие клинические рекомендации. Урология. М.: ГЭ ОТАР-Меди а; 2016.
  6. Behzadi P., Behzadi E., Yazdanbod H., Aghapour R., Akbari Cheshmeh M., Salehian Omran D. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica (Buchar.). 2010; 5(2): 111-5.
  7. Colgan R., Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am. Fam. Physician. 2011; 84(7): 771-6.
  8. Schito G.C., Naber K.G., Botto H., Palou J., Mazzei T., Gualco L., Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents. 2009; 34(5): 407-13. https://doi.org/10.1016/ j.ijantimicag.2009.04.012.
  9. Paterson D.L. «Collateral damage» from cephalosporin or quinolone antibiotic therapy. Clin. Infect Dis. 2004; 38(4): 341-5. https://doi.org/10.1086/ 382690.
  10. Hitzenbichler F., Simon M., Holzmann T., Iberer M., Zimmermann M., Salzberger B., Hanses F. Antibiotic resistance in E. coli isolates from patients with urinary tract infections presenting to the emergency department. Infection. 2018; 46(3): 325-31. https://doi.org/10.1007/s15010-018-1117-5.
  11. Anger J., Lee U., Ackerman A.L., Chou R., Chughtai B., Clemens J.Q. et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/ SUFU guideline. J. Urol. 2019; 202(2): 282-9. https://doi.org/10.1097/ JU.0000000000000296.
  12. Knothe H., Schafer V., Sammann A., Shah P.M. Influence of fosfomycin on the intestinal and pharyngeal flora of man. Infection. 1991; 19(1): 18-20.
  13. Mavromanolakis E., Maraki S., Samonis G., Tselentis Y., Cranidis A. Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. J. Chemother. 1997; 9(3): 203-7. https://doi.org/10.1179/joc.1997.9.3.203.
  14. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 2001; 1(2): 101-14. https://doi. org/10.1016/S1473-3099(01)00066-4.
  15. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitits and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011; 52(5): e103-20. https://doi. org/10.1093/cid/ciq257.
  16. Рафальский В.В. Антибиотикорезистентность возбудителей неосложненных инфекций мочевых путей в Российской Федерации. Вестник урологии. 2018; 6(3): 50-6. https://doi.org/10.21886/2308-6424-2018-6- 3-50-56.
  17. Cai T., Nesi G., Mazzoli S., Meacci F., Lanzafame P., Caciagli P. et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clin. Infect. Dis. 2015; 61(11): 1655-61. https://doi.org/10.1093/cid/civ696.
  18. Brumfitt W., Smith G.W., Hamilton-Miller J.M., Gargan R.A. A clinical comparison between Macrodantin and trimethoprim for prophylaxis in women with recurrent urinary infections. J. Antimicrob. Chemother. 1985; 16(1): 111-20. https://doi.org/10.1093/jac/16.1.111.
  19. Mozdzan M., Ruxer J., Siejka A., Loba J. The efficacy of chronic therapy of recurrent lower urinary tract infections with fosfomycin and nitrofurantoin in type 2 diabetic patients. Adv. Clin. Exp. Med. 2007; 16: 777.
  20. Oaussen K., Stocks E., Bhat D., Fish J., Rubin C.D. How common are pulmonary and hepatic adverse effects in older adults prescribed nitrofurantoin? J. Am. Geriatr. Soc. 2017; 65(6): 1316-20. https://doi.org/10.1111/jgs.14796.
  21. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2015; 63(11): 2227-46. https://doi.org/10.1111/jgs.13702.
  22. Ho J.M., Juurlink D.N. Considerations when prescribing trimethoprim -sulfamethoxazole. CMAJ. 2011; 183(16): 1851-8. https://doi.org/10.1503/ cmaj.111152.
  23. Costelloe C., Metcalfe C., Lovering A., Mant D., Hay A.D. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010; 340: 2096. https://doi. org/10.1136/bmj.c2096.
  24. World Health Organization. Antimicrobial resistance. 2018. Available at: http:// www.who.int/antimicrobial-resistance/en/
  25. Kontiokari T., Sundqvist K., Nuutinen M., Pokka T., Koskela M., Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001; 322(7302): 1571. https://doi.org/10.1136/bmj.322.7302.1571.
  26. Takahashi S., Hamasuna R., Yasuda M., Arakawa S., Tanaka K., Ishikawa K. et al. A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection. J. Infect. Chemother. 2013; 19(1): 112-7. https://doi.org/10.1007/s10156-012-0467-7.
  27. Vostalova J., Vidlar A., Simanek V., Galandakova A., Kosina P., Vacek J. et al. Are high proanthocyanidins key to cranberry efficacy in the prevention of recur rent urinary tract infection? Phytother. Res. 2015; 29(10): 1559-67. https:// doi.org/10.1002/ptr.5427.
  28. Kranjcec B., Papes D., Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J. Urol. 2014; 32(1): 79-84. https://doi.org/10.1007/s00345-013-1091-6.
  29. Porru D., Parmigiani A., Tinelli C., Barletta D., Choussos D., Di Franco C. et al. Oral D-mannose in recurrent urinary tract infections in women: A pilot study. J. Clin. Urol. 2014; 7: 208-13. https://doi.org/10.1177%2F2051415813518332
  30. Зайцев А.В., Перепанова Т.С., Гвоздев М.Ю., Арефьева О.А. Инфекции мочевыводящих путей. Методические рекомендации № 57. Департамент здравоохранения города Москва; 2017; 26.
  31. Bauer H.W., Alloussi S., Egger G., BlUmlein H.M., Cozma G., Schulman C.C. et al. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur. Urol. 2005; 47(4): 542-8. https://doi.org/10.1016/j.eururo.2004.12.009.
  32. Naber K.G., Cho Y.H., Matsumoto T., Schaeffer A.S. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int. J. Antimicrob. Agents. 2009; 33(2): 111-9. https://doi.org/10.1016/j.ijantimicag.2008.08.011.
  33. Кульчавеня Е.В. Эффективность уроваксома при рецидивирующих инфекционно-воспалительных заболеваниях мочеполовой системы. Урология. 2011; 4: 7-11.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2019

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>